The findings were presented at ASM Microbe 2023. The study utilized a proprietary blood culture identification panel and a cloud-based surveillance network to track
infection rates geographically and over time. This highlights the ongoing threat that
).
poses a serious health risk. Approximately 50% of isolates resist both disinfection and multiple
. Thus, mortality rates are high when this organism becomes established in the bloodstream. First detected in the United States in 2016, the
infection rate increased 95% by 2021.
The BioMrieux researchers analyzed C. auris detection rates in a United States cohort from 2021 to 2023 and found a significant increase in C. auris bloodstream infections in 2023 compared with infections in previous years.
Advertisement
“The study results confirm that we must continue to emphasize public health interventions under the leadership of the Centers for Disease Control and Prevention in order to meet the continuing challenge posed by antimicrobial-resistant C. auris and protect community health,” said presenting author Tristan T. Timbook, Director of Health Economics Outcomes Research, Global Medical Affairs, for bioMrieux. “The near real-time surveillance provided by TREND and the BIOFIRE BCID2 panel represent important tools for monitoring trends in C. auris infection.”
Reference:
- Drug-Resistant Candida auris Infection Rates Continue to Rise – (https://asm.org/Press-Releases/2023/June/Drug-Resistant-Candida-auris-Infection-Rates-Conti)
Source: Eurekalert
Source link
#Candida #auris #Emerging #Menace #Horizon
